Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older
Brief Summary: The purpose of this study is to demonstrate the effectiveness (seroprotection and seroconversion as measured by the hemagglutination inhibition \[HI\] assay) of an investigational Vero cell-derived, trivalent, seasonal influenza vaccine in adults 50 years of age and older. Subjects will be randomized in a double-blind fashion to receive a single intramuscular injection of either the investigational vaccine or a licensed egg-derived seasonal influenza vaccine. Blood will be drawn from all subjects for a determination of HI antibody titers on Days 0 and 21, body temperature and injection site reactions will be monitored daily for 7 days. In addition, subjects will be monitored for adverse events and rises in body temperature until Day 21 and again until Day 180.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: Vero cell derived, trivalent, seasonal influenza vaccine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Biological: Licensed egg-derived, trivalent seasonal influenza vaccine | Intervention Type: BIOLOGICAL; Name: Vero cell derived, trivalent, seasonal influenza vaccine; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Licensed egg-derived, trivalent seasonal influenza vaccine; Assigned to Arm(s): 2
B: Arm Label: A/H1N1 Vaccine Group 1; Type: EXPERIMENTAL; Interventions: Biological: Monovalent Subvirion A/H1N1 Influenza vaccine (7.5 µg of HA) | Arm Label: A/H1N1 Vaccine Group 2; Type: EXPERIMENTAL; Interventions: Biological: Monovalent Subvirion A/H1N1 Influenza vaccine (15 µg of HA) | Arm Label: A/H1N1 Vaccine Group 3; Type: EXPERIMENTAL; Interventions: Biological: Monovalent Subvirion A/H1N1 Influenza vaccine (30 µg of HA) | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Normal saline solution (placebo) | Intervention Type: BIOLOGICAL; Name: Monovalent Subvirion A/H1N1 Influenza vaccine (7.5 µg of HA); Assigned to Arm(s): A/H1N1 Vaccine Group 1 | Intervention Type: BIOLOGICAL; Name: Monovalent Subvirion A/H1N1 Influenza vaccine (15 µg of HA); Assigned to Arm(s): A/H1N1 Vaccine Group 2 | Intervention Type: BIOLOGICAL; Name: Monovalent Subvirion A/H1N1 Influenza vaccine (30 µg of HA); Assigned to Arm(s): A/H1N1 Vaccine Group 3 | Intervention Type: BIOLOGICAL; Name: Normal saline solution (placebo); Assigned to Arm(s): Placebo Group
C: Arm Label: pandemic vaccine 1; Type: EXPERIMENTAL; Interventions: Biological: pandemic vaccine 1 | Arm Label: pandemic vaccine 2; Type: EXPERIMENTAL; Interventions: Biological: pandemic vaccine 2 | Arm Label: pandemic vaccine 5; Type: EXPERIMENTAL; Interventions: Biological: pandemic vaccine 5 | Arm Label: pandemic vaccine 6; Type: EXPERIMENTAL; Interventions: Biological: pandemic vaccine 6 | Arm Label: pandemic vaccine 9; Type: EXPERIMENTAL; Interventions: Biological: pandemic vaccine 9 | Arm Label: pandemic vaccine 10; Type: EXPERIMENTAL; Interventions: Biological: pandemic vaccine 10 | Arm Label: pandemic vaccine 11; Type: EXPERIMENTAL; Interventions: Biological: pandmeic vaccine 11 | Arm Label: pandemic vaccine 12; Type: EXPERIMENTAL; Interventions: Biological: pandmeic vaccine 12 | Arm Label: pandemic vaccine 13; Type: EXPERIMENTAL; Interventions: Biological: pandmic vaccine 13 | Arm Label: placebo group 14; Type: PLACEBO_COMPARATOR; Interventions: Biological: placebo group 14 | Intervention Type: BIOLOGICAL; Name: pandemic vaccine 1; Assigned to Arm(s): pandemic vaccine 1 | Intervention Type: BIOLOGICAL; Name: pandemic vaccine 2; Assigned to Arm(s): pandemic vaccine 2 | Intervention Type: BIOLOGICAL; Name: pandemic vaccine 5; Assigned to Arm(s): pandemic vaccine 5 | Intervention Type: BIOLOGICAL; Name: pandemic vaccine 6; Assigned to Arm(s): pandemic vaccine 6 | Intervention Type: BIOLOGICAL; Name: pandemic vaccine 9; Assigned to Arm(s): pandemic vaccine 9 | Intervention Type: BIOLOGICAL; Name: pandemic vaccine 10; Assigned to Arm(s): pandemic vaccine 10 | Intervention Type: BIOLOGICAL; Name: pandmeic vaccine 11; Assigned to Arm(s): pandemic vaccine 11 | Intervention Type: BIOLOGICAL; Name: pandmeic vaccine 12; Assigned to Arm(s): pandemic vaccine 12 | Intervention Type: BIOLOGICAL; Name: pandmic vaccine 13; Assigned to Arm(s): pandemic vaccine 13 | Intervention Type: BIOLOGICAL; Name: placebo group 14; Assigned to Arm(s): placebo group 14
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: Inactivated Split-virion influenza vaccine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Biological: Inactivated Split-virion influenza vaccine | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Biological: Inactivated Split-virion influenza vaccine | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Biological: Inactivated Split-virion influenza vaccine | Intervention Type: BIOLOGICAL; Name: Inactivated Split-virion influenza vaccine; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Inactivated Split-virion influenza vaccine; Assigned to Arm(s): 2 | Intervention Type: BIOLOGICAL; Name: Inactivated Split-virion influenza vaccine; Assigned to Arm(s): 3 | Intervention Type: BIOLOGICAL; Name: Inactivated Split-virion influenza vaccine; Assigned to Arm(s): 4

Answer: A